Progressive and nonresolving pneumonia

Current Opinion in Pulmonary Medicine

Volumn 11, Issue 3, 2005, Pages 247-252

  Low, Donald E ^a,b   Mazzulli, Tony ^a,b   Marrie, Tom ^c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Community acquired pneumonia; Immune therapy; Nonresponding pneumonia; Progressive pneumonia; Treatment failures

Indexed keywords

ANTIBIOTIC AGENT; DROTRECOGIN; IMMUNOGLOBULIN G; LEUKOCIDIN; PANTON VALENTINE LEUKOCIDIN; PLACEBO; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; AVIAN INFLUENZA; CLINICAL FEATURE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; INFLUENZA VIRUS A; LABORATORY TEST; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; NONRESOLVING PNEUMONIA; PNEUMONIA; PROGRESSIVE PNEUMONIA; REVIEW; RISK FACTOR; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS GROUP A; STREPTOCOCCUS PNEUMONIA; THORAX RADIOGRAPHY; TREATMENT FAILURE; VIRUS LOAD;

ALBERTA; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DISEASE PROGRESSION; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, BACTERIAL; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT FAILURE;

EID: 17744390226     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Marrie TJ, Campbell GD, Walker DH, Low DE. Pneumonia. In: Kasper DL, Braunwald E, Fauci AS, et al., editors. Principles of internal medicine. 16th ed. New York: McGraw Hill; 2004. pp. 1528-1541.
2. Menendez R, Perpina M, Torres A. Evaluation of nonresolving and progressive pneumonia. Semin Respir Infect 2003; 18:103-111.
3. Rome L, Murali G, Lippmann M. Nonresolving pneumonia and mimics of pneumonia. Med Clin North Am 2001; 85:1511-1530. (xi.)
4. Cunha BA. Slowly resolving and nonresolving pneumonias. Drugs Today (Barc) 2000; 36:829-834.
5. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163:1730-1754.
6. Ortqvist A, Kalin M, Lejdeborn L, Lundberg B. Diagnostic fiberoptic bronchoscopy and protected brush culture in patients with community-acquired pneumonia. Chest 1990; 97:576-582.
7. Arancibia F, Ewig S, Martinez JA, et al. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med 2000; 162:154-160.
8. El Solh AA, Aquilina AT, Gunen H, Ramadan F. Radiographic resolution of community-acquired bacterial pneumonia in the elderly. J Am Geriatr Soc 2004; 52:224-229. This paper examines how long radiographic resolution of nontuberculous bacterial pneumonia in the elderly should take.
9. Kuru T, Lynch JP III. Nonresolving, slowly resolving, and recurrent pneumonia: infectious etiologies and noninfectious mimics. In: Niederman M, Sarosi GA, Glassroth J, editors. Respiratory infections. 2nd ed. New York: Lippincott Williams and Wilkins; 2001. pp. 317-331.
10. Fein AM, Feinsilver SH. The approach to nonresolving pneumonia in the elderly. Semin Respir Infect 1993; 8:59-72.
11. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia [see comments]. N Engl J Med 1997; 336:243-250.
12. Halm EA, Teirstein AS. Clinical practice: management of community-acquired pneumonia. N Engl J Med 2002; 347:2039-2045.
13. Neill AM, Martin IR, Weir R, et al. Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 1996; 51:1010-1016.
14. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58:377-382.
15. Cassiere H, Rodrigues JC, Fein AM. Delayed resolution of pneumonia: when is slow healing too slow? Postgrad Med 1996; 99:151-158.
16. Menendez R, Torres A, Zalacain R, et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004; 59:960-965. This paper identifies risk factors for empirical treatment failure of CAP and determines the implications of such on the outcome.
17. Roson B, Carratala J, Fernandez-Sabe N, et al. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 2004; 164:502-508. This paper reports a prospective observational analysis of the causes and risk factors for early therapy failures in hospitalised patients with CAP.
18. Mazzulli T, Kain K, Butany J. Severe acute respiratory syndrome: overview with an emphasis on the Toronto experience. Arch Pathol Lab Med 2004; 128:1346-1350.
19. Poutanen SM, Low DE. Severe acute respiratory syndrome: an update. Curr Opin Infect Dis 2004; 17:287-294.
20. Christian MD, Poutanen SM, Loutfy MR, et al. Severe acute respiratory syndrome. Clin Infect Dis 2004; 38:1420-1427.
21. Bitar R, Weiser WJ, Avendano M, et al. Chest radiographic manifestations of severe acute respiratory syndrome in health care workers: the Toronto experience. AJR Am J Roentgenol 2004; 182:45-48.
22. Ng EKO, Hui DS, Chan KCA, et al. Quantitative analysis and prognostic implication of SARS coronavirus RNA in the plasma and serum of patients with Severe Acute Respiratory Syndrome. Clin Chem 2003; 49:1976-1980.
23. Farcas GA, Poutanen SM, Mazzulli T, et al. Fatal severe acute respiratory syndrome is associated with multiorgan involvement by coronavirus. J Infect Dis 2005; 191:193-197. This paper reports the results of patients with SARS who had undergone autopsies. It is one of the few comprehensive reports of a large number of patients dying from SARS.
24. Mazzulli T, Farcas GA, Poutanen SM, et al. Severe acute respiratory syndrome-associated coronavirus in lung tissue. Emerg Infect Dis 2004; 10:20-24.
25. Hwang DM, Chamberlain DW, Poutanen SM, et al. Pulmonary pathology of severe acute respiratory syndrome in Toronto. Mod Pathol 2005; 18:1-10.
26. Yuen KY, Chan PK, Peiris M, et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 1998; 351:467-471.
27. Muller MP, Low DE, Green KA, et al. Clinical and epidemiologic features of group a streptococcal pneumonia in Ontario, Canada. Arch Intern Med 2003; 163:467-472.
28. Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus: Minnesota and North Dakota, 1997-1999. JAMA 1999; 282:1123-1125.
29. Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002; 359:753-759.
30. Lina G, Piemont Y, Godail-Gamot F, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999; 29:1128-1132.
31. Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005; 40:100-107.
32. Austrian R, Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964; 60:759-770.
33. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138-150.
34. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein for severe sepsis. N Engl J Med 2001; 344:699-709.
35. Kaul R, McGeer A, Norrby-Teglund A, et al. The Canadian Streptococcal Study Group. Intravenous immunoglobulin therapy in streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis 1999; 28:800-807.
36. Darenberg J, Ihendyane N, Sjolin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003; 37:333-340.
37. Norrby-Teglund A, Norrby SR, Low DE. The treatment of severe group A streptococcal infections. Curr Infect Dis Rep 2003; 5:28-37. et al.